Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
1–1
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy participants of either gender
Aged 12 to 23 months
No clinical history of measles, mumps, rubella, varicella and zoster
For Italy: Primary vaccination with the combined diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine Infanrix® hexa as a 2-dose schedule, with receipt of the second dose ≥ 6 months prior to inclusion
For Germany: Primary vaccination with the combined diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine Infanrix® hexa as a 3-dose schedule, with receipt of the third dose ≥ 6 months prior to inclusion
Consent form signed by parent(s) according to local regulations or by the legal representative properly informed about the study
Parent(s)/legal representative able to understand the protocol requirements and to fill in the Diary Card.
You may not be if
Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in any combination
Any recent (\<= 30 days) exposure to measles, mumps, rubella, varicella and/or zoster
Receipt of any other diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and/or Haemophilus influenzae type b containing vaccine (either alone or in any combination) than Infanrix® hexa
Any recent (\<= 3 days) history of febrile illness
Any severe chronic disease
Active untreated tuberculosis
Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition
Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic or lymphatic systems
Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection
Prior known sensitivity/allergy to any component of the vaccines including neomycin, sorbitol or gelatin
Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity
Any recent (\<= 2 days) tuberculin test or scheduled tuberculin test through Visit 2
Any previous (\<= 150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through Visit 2
Any recent (\<= 30 days) receipt of an inactivated or a live non-study vaccine or scheduled non-study vaccination through Visit 2
Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives
Any recent (≤30 days) participation or scheduled participation in any other clinical trial through Visit 2